Disulfiram for Rheumatoid Arthritis

This trial investigates whether disulfiram, a drug typically used to treat alcohol addiction, can reduce inflammation and improve symptoms in individuals with rheumatoid arthritis (RA), particularly those who are overweight or obese. Researchers aim to assess its safety and effectiveness in lowering inflammation in the body and joints. Participants will receive either disulfiram or a placebo (a harmless pill with no active drug) alongside their regular RA medication. Individuals with RA who have active symptoms and are willing to abstain from alcohol during the study might be suitable candidates. The results could lead to larger studies focused on new treatments for RA. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group of people.

The trial does not specify if you need to stop taking your current medications, but you must have been on stable RA medication for at least 3 months before joining. Some medications, like metronidazole and warfarin, are not allowed during the trial.

Research has shown that disulfiram, a drug commonly used to treat alcohol addiction, is being studied for its potential to reduce inflammation. Studies have found that disulfiram can decrease certain inflammatory processes, which might help with conditions like rheumatoid arthritis.

Regarding safety, real-world data has examined side effects linked to disulfiram. Results suggest that while disulfiram is generally well-tolerated, it can cause some side effects, such as tiredness or mild stomach issues. However, serious side effects are rare.

Unlike the standard treatments for rheumatoid arthritis, which often include DMARDs like methotrexate and biologics targeting specific immune pathways, disulfiram is unique because it is originally an anti-alcoholism drug with potential anti-inflammatory effects. Researchers are excited about disulfiram because it might modulate the immune system differently, potentially reducing inflammation and joint damage in a new way. This new mechanism of action could offer an alternative for patients who don't respond well to existing therapies, providing a fresh hope for better management of rheumatoid arthritis.

Research suggests that disulfiram, a drug typically used to treat alcohol addiction, might aid in managing rheumatoid arthritis (RA). Early laboratory studies have shown that disulfiram can reduce inflammation and improve bodily function by blocking specific pathways that cause inflammation. Specifically, it inhibits pathways linked to joint inflammation and RA severity. Initial research also indicates it might reduce the activation of inflammasomes, which can worsen RA symptoms. Although more studies with people are needed, these findings suggest disulfiram could help manage RA by directly targeting inflammation. Participants in this trial will receive either disulfiram or a placebo to assess its effectiveness in managing RA symptoms.¹³⁵⁶⁷